Clinical outcomes of the EyeWatch system: three-year results.
Summary
Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention.
Abstract
WHAT IS KNOWN
The EyeWatch™ System (EWS) is an adjustable glaucoma drainage device that allows non-invasive postoperative intraocular pressure (IOP) control. Early studies have shown promising short- and mid-term results with EWS in managing refractory glaucoma.
WHAT IS NEW
This study presents the first three-year clinical outcomes of EWS implantation, showing a sustained IOP reduction from a preoperative mean of 34.6 mmHg to 13.6 mmHg, with all patients achieving IOP levels below 21 mmHg and a significant decrease in medication burden. Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention. A transient IOP elevation following MRI underscores the importance of monitoring EWS patients in the context of magnetic exposure.
Keywords
More by Constance Liegl
View full profile →Clinical outcomes of the PAUL glaucoma implant in primary open-angle and pseudoexfoliative glaucoma eyes after failed glaucoma surgeries.
Clinical outcomes of the PAUL® Glaucoma implant for refractory glaucoma: three-year results.
Comparing the use of Tutopatch® pericardium with Tutoplast® fascia lata in the context of PAUL® glaucoma implant surgery: an anterior segment OCT study.
Top Research in IOP & Medical Therapy
Browse all →The Complications of Myopia: A Review and Meta-Analysis.
Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up.
Discussion
Comments and discussion will appear here in a future update.